Decernotinib

Decernotinib
Identifiers

IUPAC name (2R)-2-Methyl-2-[[2-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]-N-(2,2,2-trifluoroethyl)butanamide
CAS Number	944842-54-0
PubChem CID	59422203
ChemSpider	30843790
UNII	MZK2GP0RHK
KEGG	D10585
CompTox Dashboard (EPA)	DTXSID70241504
Chemical and physical data
Formula	C₁₈H₁₉F₃N₆O
Molar mass	392.386 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC[C@](C)(C(=O)NCC(F)(F)F)NC1=NC(=NC=C1)C2=CNC3=C2C=CC=N3
InChI InChI=1S/C18H19F3N6O/c1-3-17(2,16(28)25-10-18(19,20)21)27-13-6-8-23-15(26-13)12-9-24-14-11(12)5-4-7-22-14/h4-9H,3,10H2,1-2H3,(H,22,24)(H,25,28)(H,23,26,27)/t17-/m1/s1 Key:ASUGUQWIHMTFJL-QGZVFWFLSA-N

Decernotinib is an inhibitor of Janus kinase 3 (JAK3) discovered through a process of inhouse screening of a chemical compound library. Decernotinib also had the name VX-509 in development phase. It is an experimental drug with high selectivity for JAK3, which demonstrates good efficacy in vivo in the rat host versus graft model (HvG). It is being studied in clinical trials at Vertex.^[1]

References

^ Farmer LJ, Ledeboer MW, Hoock T, Arnost MJ, Bethiel RS, Bennani YL, et al. (September 2015). "Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases". Journal of Medicinal Chemistry. 58 (18): 7195–216. doi:10.1021/acs.jmedchem.5b00301. PMID 26230873.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

This page was last edited on 25 March 2021, at 10:39

From Wikipedia, the free encyclopedia

References